ArticleTranslational lung cancer research2024

Real-world efficacy of low dose osimertinib as second-line treatment in patients with epidermal growth factor receptor-mutated advanced non-small cell lung cancer.

Mau Ern Poh et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.